# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 521-530 of 560 results.
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
Status: Available
Last Changed: Jul 17, 2020
First Received: Jul 04, 2016
Disease(s): Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Epstein-Barr Viremia, Lymphoma, AIDS-related, Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID), Leiomyosarcoma (LMS), Nasopharyngeal Carcinoma (NPC), Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Acquired Immunodeficiency (AID), Solid Organ Transplant Complications, Stem Cell Transplant Complications
Intervention(s): tabelecleucel
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Status: Recruiting
Last Changed: Jul 02, 2020
First Received: Dec 09, 2009
Disease(s): Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission, Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM, Acute Myeloid Leukemia With Multilineage Dysplasia, Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1), B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Burkitt Lymphoma, Childhood Acute Lymphoblastic Leukemia in Complete Remission, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Myelodysplastic Syndrome, Recurrent Anaplastic Large Cell Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Recurrent Follicular Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Secondary Acute Myeloid Leukemia, T Lymphoblastic Lymphoma, Hematopoietic Cell Transplant Recipient
Intervention(s): Cyclophosphamide, Filgrastim, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation, Fludarabine
Locations: VA Puget Sound Health Care System, Seattle, Washington, United States
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
Status: Recruiting
Last Changed: May 07, 2020
First Received: Nov 23, 2000
Disease(s): HIV, Kaposi's Sarcoma, Lymphomas, Multicentric Castleman's Disease, Primary Effusion Lymphoma
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Treatment and Natural History Study of Lymphomatoid Granulomatosis
Status: Recruiting
Last Changed: Jul 30, 2020
First Received: Nov 04, 1999
Disease(s): Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid, Non-Hodgkins Lymphoma, Lymphoproliferative Disorder
Intervention(s): Interferon, Rituxan and EPOCH
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma
Status: Recruiting
Last Changed: Jul 01, 2020
First Received: Jan 21, 2020
Disease(s): Mantle Cell Lymphoma Recurrent
Intervention(s): ibrutinib and Tisagenlecleucel
Locations: Peter Mac Callum Cancer Centre, Melbourne, Victoria, Australia
Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality
Status: Not yet recruiting
Last Changed: Aug 03, 2020
First Received: Jul 30, 2020
Disease(s): Hypogonadism
Intervention(s): AndroGel
Locations: Copenhagen University Hospital, Copenhagen, Denmark
Herlev University Hospital, Herlev, Denmark
Zealand University Hospital, Roskilde, Denmark
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
Status: Recruiting
Last Changed: Feb 07, 2020
First Received: Sep 20, 2013
Disease(s): Lymphoid Malignancies, Multiple Myeloma, Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
Intervention(s): Pralatrexate, Romidepsin
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Columbia University Irving Medical Center, New York, New York, United States
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Status: Recruiting
Last Changed: Feb 17, 2020
First Received: Feb 17, 2020
Disease(s): Leukemia, Lymphoma, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
Intervention(s): CD19 CAR-T cells
Locations: Chongqing University Cancer Hospital, Chongqing, Chongqing, China
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
Status: Recruiting
Last Changed: Jul 28, 2020
First Received: Apr 30, 2019
Disease(s): Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia
Intervention(s): Acalabrutinib
Locations: Research Site, Beijing, China
Research Site, Beijing, China
Research Site, Beijing, China
Research Site, Changsha, China
Research Site, Changzhou, China
... and 19 other locations.
A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome
Status: Not yet recruiting
Last Changed: Apr 02, 2019
First Received: Apr 02, 2019
Disease(s): Richter Syndrome
Intervention(s): Acalabrutinib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Rituximab